Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Ischemia Reperfusion Injury Overview 8 Therapeutics Development 9 Pipeline Products for Ischemia Reperfusion Injury - Overview 9 Pipeline Products for Ischemia Reperfusion Injury - Comparative Analysis 10 Ischemia Reperfusion Injury - Therapeutics under Development by Companies 11 Ischemia Reperfusion Injury - Therapeutics under Investigation by Universities/Institutes 14 Ischemia Reperfusion Injury - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Ischemia Reperfusion Injury - Products under Development by Companies 19 Ischemia Reperfusion Injury - Products under Investigation by Universities/Institutes 22 Ischemia Reperfusion Injury - Companies Involved in Therapeutics Development 24 Amyndas Pharmaceuticals LLC 24 Angion Biomedica Corp. 25 Antipodean Pharmaceuticals, Inc. 26 Bayer AG 27 Biomedica Management Corporation 28 Bolder Biotechnology, Inc. 29 Curatis Pharma GmbH 30 Ensemble Therapeutics Corporation 31 Erimos Pharmaceuticals, LLC 32 Gilead Sciences, Inc. 33 Ischemix, Inc. 34 Kowa Company, Ltd. 35 LG Life Science LTD. 36 Magnus Life Science 37 NeuroVive Pharmaceutical AB 38 Nyken B.V. 39 Omeros Corporation 40 Opsona Therapeutics Limited 41 Orexo AB 42 Pharming Group N.V. 43 PledPharma AB 44 Prolong Pharmaceuticals 45 Proteo, Inc. 46 Prothix BV 47 Stealth BioTherapeutics Inc. 48 Zealand Pharma A/S 49 Ischemia Reperfusion Injury - Therapeutics Assessment 50 Assessment by Monotherapy Products 50 Assessment by Target 51 Assessment by Mechanism of Action 55 Assessment by Route of Administration 58 Assessment by Molecule Type 60 Drug Profiles 62 AER-271 - Drug Profile 62 AM/AMBP-1 - Drug Profile 63 ANV-6L15 - Drug Profile 66 APP-103 - Drug Profile 67 BAY-606583 - Drug Profile 68 BB-3 - Drug Profile 69 BBT-059 - Drug Profile 73 bucillamine - Drug Profile 74 C1 esterase inhibitor (human) - Drug Profile 75 CMX-2043 - Drug Profile 80 CRX-526 - Drug Profile 82 Curaglutide - Drug Profile 83 danegaptide - Drug Profile 84 Des-Asp Angiotensin 1 - Drug Profile 86 Drugs to Inhibit ADAM17 for Ischemia Reperfusion Injury - Drug Profile 87 EP-80317 - Drug Profile 88 GS-459679 - Drug Profile 89 KN-93 - Drug Profile 90 LH-021 - Drug Profile 92 mangafodipir trisodium - Drug Profile 93 MG-53 - Drug Profile 94 mirococept - Drug Profile 96 MitoQ - Drug Profile 98 Monoclonal Antibody for Ischemia Reperfusion Injury - Drug Profile 100 Monoclonal Antibody to Inhibit CD47 for Cardiovascular Disease, Kidney Transplantation and Oncology - Drug Profile 101 Monoclonal Antibody to Inhibit IL-16 for Renal Ischemia Reperfusion Injury - Drug Profile 103 MTP-131 - Drug Profile 104 NBD Peptide - Drug Profile 106 NecX - Drug Profile 108 Neutrolide - Drug Profile 109 NP-202 - Drug Profile 111 NVP-019 - Drug Profile 113 NYK-1112 - Drug Profile 114 Oligonucleotide for Oncology and Cardiovascular - Drug Profile 115 OMS-721 - Drug Profile 116 OPN-305 - Drug Profile 118 PAC-G31P - Drug Profile 120 PIN-201601 - Drug Profile 122 pitavastatin NP - Drug Profile 123 PMC-6 - Drug Profile 124 PRO-02 - Drug Profile 125 R-190 - Drug Profile 126 Recombinant Peptide to Activate FPR2 for Ischemia Reperfusion Injury and Myocardial Ischemia - Drug Profile 128 Recombinant Protein for Sepsis, Inflammatory Bowel Disease, Acute Kidney Injury, Acute Radiation Syndrome and Ischemic Organ Injury - Drug Profile 129 Recombinant Protein Slit2 to Agonize Robo1 for Ischemia Reperfusion Injury and Thrombosis - Drug Profile 131 Recombinant Protein to Inhibit CXCL for Pancreatitis, Cardiovascular and Immunology - Drug Profile 132 Recombinant Proteins for Ischemia Reperfusion Injury and Hypoxia - Drug Profile 133 Recombinant Proteins to Agonize PTCH1 for Ischemia Reperfusion Injury - Drug Profile 134 Recombinat Protein to Antagonize Interleukin-1 Receptor for Cardiomyopathy and Ischemia Reperfusion Injury - Drug Profile 135 Sanguinate - Drug Profile 136 Small Molecule for Reperfusion Injury and Heart Attack - Drug Profile 138 Small Molecule to Agonize Opioid Delta for Reperfusion Injury - Drug Profile 139 Small Molecule to Inhibit Arginase-1 and Arginase-2 for Myocardial Ischemia and Ischemia Reperfusion Injury - Drug Profile 140 Small Molecules for Ischemia Reperfusion Injury - Drug Profile 141 Small Molecules for Ischemia Reperfusion Injury - Drug Profile 142 Small Molecules for Ischemia Reperfusion Injury - Drug Profile 143 Small Molecules for Ischemia Reperfusion Injury and Inflammation - Drug Profile 144 Small Molecules to Activate SGK-1 for Ischemic Reperfusion Injury - Drug Profile 145 Small Molecules to Inhibit Cyclophilin D for Reperfusion Injury and Alzheimer's Disease - Drug Profile 146 Small Molecules to Inhibit PDE5 for Cardiovascular Disease - Drug Profile 147 Synthetic Peptides for Ischemia Reperfusion Injury - Drug Profile 148 Synthetic Peptides for Oncology, Immunology and Cardiovascular Disorders - Drug Profile 149 terameprocol - Drug Profile 150 tiomolibdate diammonium - Drug Profile 152 tiprelestat - Drug Profile 153 TMS-007 - Drug Profile 156 UCF-101 - Drug Profile 157 UWA-TAT - Drug Profile 158 Ischemia Reperfusion Injury - Recent Pipeline Updates 159 Ischemia Reperfusion Injury - Dormant Projects 178 Ischemia Reperfusion Injury - Discontinued Products 184 Ischemia Reperfusion Injury - Product Development Milestones 185 Featured News & Press Releases 185 Appendix 194 Methodology 194 Coverage 194 Secondary Research 194 Primary Research 194 Expert Panel Validation 194 Contact Us 194 Disclaimer 195

List of Tables Number of Products under Development for Ischemia Reperfusion Injury, H1 2016 14 Number of Products under Development for Ischemia Reperfusion Injury - Comparative Analysis, H1 2016 15 Number of Products under Development by Companies, H1 2016 16 Number of Products under Development by Companies, H1 2016 (Contd..1) 17 Number of Products under Development by Companies, H1 2016 (Contd..2) 18 Number of Products under Investigation by Universities/Institutes, H1 2016 19 Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 20 Comparative Analysis by Late Stage Development, H1 2016 21 Comparative Analysis by Clinical Stage Development, H1 2016 22 Comparative Analysis by Early Stage Development, H1 2016 23 Products under Development by Companies, H1 2016 24 Products under Development by Companies, H1 2016 (Contd..1) 25 Products under Development by Companies, H1 2016 (Contd..2) 26 Products under Investigation by Universities/Institutes, H1 2016 27 Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 28 Ischemia Reperfusion Injury - Pipeline by Amyndas Pharmaceuticals LLC, H1 2016 29 Ischemia Reperfusion Injury - Pipeline by Angion Biomedica Corp., H1 2016 30 Ischemia Reperfusion Injury - Pipeline by Antipodean Pharmaceuticals, Inc., H1 2016 31 Ischemia Reperfusion Injury - Pipeline by Bayer AG, H1 2016 32 Ischemia Reperfusion Injury - Pipeline by Biomedica Management Corporation, H1 2016 33 Ischemia Reperfusion Injury - Pipeline by Bolder Biotechnology, Inc., H1 2016 34 Ischemia Reperfusion Injury - Pipeline by Curatis Pharma GmbH, H1 2016 35 Ischemia Reperfusion Injury - Pipeline by Ensemble Therapeutics Corporation, H1 2016 36 Ischemia Reperfusion Injury - Pipeline by Erimos Pharmaceuticals, LLC, H1 2016 37 Ischemia Reperfusion Injury - Pipeline by Gilead Sciences, Inc., H1 2016 38 Ischemia Reperfusion Injury - Pipeline by Ischemix, Inc., H1 2016 39 Ischemia Reperfusion Injury - Pipeline by Kowa Company, Ltd., H1 2016 40 Ischemia Reperfusion Injury - Pipeline by LG Life Science LTD., H1 2016 41 Ischemia Reperfusion Injury - Pipeline by Magnus Life Science, H1 2016 42 Ischemia Reperfusion Injury - Pipeline by NeuroVive Pharmaceutical AB, H1 2016 43 Ischemia Reperfusion Injury - Pipeline by Nyken B.V., H1 2016 44 Ischemia Reperfusion Injury - Pipeline by Omeros Corporation, H1 2016 45 Ischemia Reperfusion Injury - Pipeline by Opsona Therapeutics Limited, H1 2016 46 Ischemia Reperfusion Injury - Pipeline by Orexo AB, H1 2016 47 Ischemia Reperfusion Injury - Pipeline by Pharming Group N.V., H1 2016 48 Ischemia Reperfusion Injury - Pipeline by PledPharma AB, H1 2016 49 Ischemia Reperfusion Injury - Pipeline by Prolong Pharmaceuticals, H1 2016 50 Ischemia Reperfusion Injury - Pipeline by Proteo, Inc., H1 2016 51 Ischemia Reperfusion Injury - Pipeline by Prothix BV, H1 2016 52 Ischemia Reperfusion Injury - Pipeline by Stealth BioTherapeutics Inc., H1 2016 53 Ischemia Reperfusion Injury - Pipeline by Zealand Pharma A/S, H1 2016 54 Assessment by Monotherapy Products, H1 2016 55 Number of Products by Stage and Target, H1 2016 57 Number of Products by Stage and Mechanism of Action, H1 2016 61 Number of Products by Stage and Route of Administration, H1 2016 64 Number of Products by Stage and Molecule Type, H1 2016 66 Ischemia Reperfusion Injury Therapeutics - Recent Pipeline Updates, H1 2016 164 Ischemia Reperfusion Injury - Dormant Projects, H1 2016 183 Ischemia Reperfusion Injury - Dormant Projects (Contd..1), H1 2016 184 Ischemia Reperfusion Injury - Dormant Projects (Contd..2), H1 2016 185 Ischemia Reperfusion Injury - Dormant Projects (Contd..3), H1 2016 186 Ischemia Reperfusion Injury - Dormant Projects (Contd..4), H1 2016 187 Ischemia Reperfusion Injury - Dormant Projects (Contd..5), H1 2016 188 Ischemia Reperfusion Injury - Discontinued Products, H1 2016 189 List of Figures Number of Products under Development for Ischemia Reperfusion Injury, H1 2016 14 Number of Products under Development for Ischemia Reperfusion Injury - Comparative Analysis, H1 2016 15 Number of Products under Development by Companies, H1 2016 16 Number of Products under Investigation by Universities/Institutes, H1 2016 19 Comparative Analysis by Clinical Stage Development, H1 2016 22 Comparative Analysis by Early Stage Products, H1 2016 23 Assessment by Monotherapy Products, H1 2016 55 Number of Products by Top 10 Targets, H1 2016 56 Number of Products by Stage and Top 10 Targets, H1 2016 56 Number of Products by Top 10 Mechanism of Actions, H1 2016 60 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 60 Number of Products by Top 10 Routes of Administration, H1 2016 63 Number of Products by Stage and Top 10 Routes of Administration, H1 2016 63 Number of Products by Top 10 Molecule Types, H1 2016 65 Number of Products by Stage and Top 10 Molecule Types, H1 2016 65

Amyndas Pharmaceuticals LLC Angion Biomedica Corp. Antipodean Pharmaceuticals, Inc. Bayer AG Biomedica Management Corporation Bolder Biotechnology, Inc. Curatis Pharma GmbH Ensemble Therapeutics Corporation Erimos Pharmaceuticals, LLC Gilead Sciences, Inc. Ischemix, Inc. Kowa Company, Ltd. LG Life Science LTD. Magnus Life Science NeuroVive Pharmaceutical AB Nyken B.V. Omeros Corporation Opsona Therapeutics Limited Orexo AB Pharming Group N.V. PledPharma AB Prolong Pharmaceuticals Proteo, Inc. Prothix BV Stealth BioTherapeutics Inc. Zealand Pharma A/S